![Mayo Clinic home page [logo]](/images-global/mayologo.gif)
Discover how you can help support Mayo Clinic.
Below is a list of Non-Hodgkin Lymphoma clinical trials from the clinical trials database at Mayo Clinic.
This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.
Phase 3 Trial Comparing Two Different Rituximab (Rituxan) Dosing Regimens for Patients with Indolent Non-Hodgkin Lymphoma
After treatment with standard dose rituximab, this study is being done to see if single doses of rituximab given at 12-week time periods can control the disease longer compared to giving rituximab once a week for four weeks in a row at time of disease progression.
This research study includes a laboratory study that will mathematically relate the rituximab levels in a patient's blood to their response to rituximab. Patients do not have to be in the laboratory study to take part in the treatment study.
Read more
A Phase 2 Study of SGN-40 (anti-huCD40 monoclonal antibody) in Patients with Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
This study is being done to find out what effects (good and bad) SGN-40 has on a patient and large B-cell lymphoma tumors. SGN-40 is an investigational drug, which means it has not been approved for use by the U.S. Food and Drug Administration (FDA). SGN-40 is a monoclonal antibody drug. An antibody is a type of protein that helps protect the body against foreign materials such as bacteria (germs) and viruses. Monoclonal antibodies are proteins that are designed to attack specific targets on cells. SGN-40 is an antibody which is made from human protein and which reacts with the target, CD40, on white blood cells and tumor cells.
Read more
A Phase 3 Clinical Trial of the Efficacy and Safety of Subsequent Treatment with the Zevalin (ibritumomab tiuxetan) Study Regimen Versus Observation in Patients with Diffuse Large B-Cell Lymphoma Who are in Complete Remission After First-Line CHOP-Rituximab (CHOP-R) Therapy
This study is being done to find out what effects (good and bad) the drug regimen Zevalin has on a patient and their cancer. Zevalin has been approved by the U.S. Food and Drug Administration (FDA) for one type of lymphoma. This study is being performed to see if the treatment can also be used safely and effectively in patients with a different type of lymphoma known as diffuse large B-cell lymphoma (DLBCL). The use of Zevalin for the treatment of DLBCL is experimental.
The Zevalin regimen includes treatment with two different monoclonal antibodies: rituximab (Rituxan) and ibritumomab tiuxetan (Zevalin). An antibody is a type of protein found in the blood that helps protect the body against foreign matter such as bacteria and viruses. A monoclonal antibody is an antibody produced in the laboratory that attaches to specific kinds of cells. The Zevalin antibodies attach specifically to lymphoma cells. Antibodies can be administered alone, as with rituximab. Or, as with ibritumomab tiuxetan, they can carry small particles of radiation, allowing them to kill several cancer cells at one time.
Read more
A Phase 3 Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine
This study is being done to:
- Determine the effects (good and bad) of changing from the standard drug vincristine to the drug vinblastine in treating anaplastic large-cell lymphoma (ALCL) and whether or not it will help more patients' disease to get better and stay better
- Gain more understanding of the biology of ALCL and how certain biological markers might relate to treatment outcome
Patients are being asked to take part in this study because they have ALCL, a cancer of the lymphatic tissue. Lymphatic tissue carries lymphocytes to all parts of the body.
Lymphocytes are a special type of white blood cell. The type of ALCL that patients in this study have is at an advanced stage that might not respond as well to treatment. A drug called vinblastine has been shown to achieve remission in patients with ALCL that relapses. Remission occurs when there is no longer any sign of the disease, but if the cancer comes back, then it is considered to have relapsed. In this study, researchers want to see if using Vinblastine in the first treatment of ALCL works better than the standard treatment, which uses a drug called vincristine.
Read more
A Phase I/II Multi-Center, Open Label Trial of the Safety and Efficacy of R935788 in Patients With Relapsed/Refractory (Resistant) B-Cell Lymphoma
R935788 (for convenience, referred to as R788) is an investigational drug that is being developed for the treatment of B-cell lymphoma. When R788 is broken down in the body it is converted to R940406 (referred to as R406). An investigational drug is one that is not approved by the U.S. Food and Drug Administration (FDA) for use in the United States, but may be used in research studies such as this one.
B-cell lymphoma is a cancer of the white blood cells (also called lymphocytes) that grow abnormally and can grow in many parts of the body, including the lymph nodes, spleen, bone marrow, blood, or other organs.
The purpose of this research study is to see if R788 is safe and effective in controlling lymphoma cancer when it is taken at two different doses, either 200 milligrams (mg) twice a day or 250 mg twice a day. The study will be conducted at many sites and enroll up to 60 patients.
Read more
A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib (Bay 43-9006) in Combination with the mTOR Inhibitor RAD001 (Everolimus, Certican) in Patients with Relapsed Non-Hodgkins Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma
Sorafenib and RAD001 are two drugs that block some of the main switch pathways in tumor cells from working properly. When combined, it is hoped that they might prevent the cells from growing or cause them to die. Preliminary experiments with RAD001 in lymphoma patients have shown definite anti-tumor activity.
Read more
A Pilot Study to Determine the Toxicity of the Addition of Rituximab to the Induction and Consolidation Phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated with LMB/FAB Therapy
This study is being done to:
- Find out the effects, good and bad, of adding two new drugs, rituximab and rasburicase, to the standard chemotherapy drugs
- Find out the effects, good and bad, of rasburicase when given to see if it can lower the uric acid levels (salts found in patient's bloodstream)
- Compare the amount of cancer cells in the body before, during and after treatment
- Find out if there are proteins or genetic information (genes patients inherit from their parents) in the tumor cells that can tell researchers the best way to treat children with B-cell leukemia/lymphoma.
Non-Hodgkin's lymphoma is a cancer of the lymph nodes (tissue throughout the body that filters disease germs from the blood). B-cell leukemia is cancer of the blood that develops in the bone marrow where blood cells are made. (ALL is a disease in which too many underdeveloped [not normal] infection-fighting white blood cells (blasts) crowd out the normal cells).
The first investigational drug, rituximab, is an anti-cancer drug that attaches to lymphoma cells and causes these cancer cells to die by stimulating the body's own immune system (the system that recognizes and attacks cells that are not normal body cells). Rituximab has been given safely along with standard chemotherapy to adult NHL patients.
However, rituximab has not yet been used in combination with standard chemotherapy to treat children.
The second drug given on this trial is called rasburicase. Rasburicase is a drug that lowers uric acid levels in the blood. Uric acid levels go up because of the death of the normal cells and tumor cells when the chemotherapy is given. Too much uric acid in the blood can cause the kidneys to fail. Researchers want to see if rasburicase can lower the uric acid levels, but they also need to find out what kind of side effects children may have when they take rasburicase. The standard drugs used to treat B-cell lymphoma are vincristine, prednisone and cyclophosphamide.
Read more
Drug Therapy Treatment of Relapsed and Refractory Non-Hodgkin's Lymphoma
This study is being done to:
Imaging Cells in Monoclonal Antibody Therapy for Lymphoma
This study is being done to learn about how and/or why Rituxan works in the body. It is designed to help to find out how cancer-fighting cells in the body move into the tumor before and after Rituxan is given
Read more
Immunosuppressant, Alefacept (Amevive), in the Treatment of Cutaneous T-Cell Lymphoma and Peripheral T-Cell Non-Hodgkin Lymphoma (LS058C)
This study is being done to test the safety of alefecept (Amevive) and see what effects (good and bad) it has on the patient and lymphoma. The study will find the best dose of alefacept (Amevive) that will produce response in the tumor without causing severe side effects. This research is being done so researchers can find better treatments for people with T-cell lymphoma.
This research study is being done by the Lymphoma SPORE (Specialized Program of Research Excellence). The Lymphoma SPORE is a group of 2 health care centers, Mayo Clinic Rochester and the University of Iowa, that have joined together to research lymphoma and lymphoma treatments. For this study, Mayo Clinic Rochester and the University of Iowa are working with other institutions (City of Hope and John Hopkins) who have been awarded SPORE grants from the NCI. The SPORE is supported by the National Cancer Institute. Mayo Clinic Rochester is the coordinating site for the SPORE.
Read more
MC0312, Phase I/II Study of Anti-CLTLA-A Monoclonal Antibody (MDX-010) in Follicular Non-Hodgkin's Lymphoma
This research study is being done to:
" see what effects (good and bad) that an investigational (experimental) drug called MDX-010 has in patients with follicular non-hodgkin's lymphoma,
" determine which of two different doses of MDX-010 (a drug) can be given without causing bad side effects, and
" to learn how the body handles or processes the drug and the drug's other effects in the body using blood and tissue samples.
MDX-010 is a monoclonal antibody called anti-CTLA-4. The first part of this study (Phase I) will be to determine what dose of the drug can be given without causing severe side effects, and the second part (Phase II) will be to test the safety of MDX-010 and see what effects (good and bad) it has on your cancer.
Read more
Monoclonal Antibody and Chemotherapy, R-CHOP, with Radioimmunotherapy, Zevalin, for Patients with Previously Untreated Stages 1 and 2 CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma
This study is being done to find out what effects (good and bad) a new treatment that combines standard CHOP chemotherapy [cyclophosphamide, hydroxydaunomycin (doxorubicin), oncovin (vincristine) and prednisone] with a monoclonal antibody (rituximab) followed by a single dose of a radioactive antibody (zevalin) has on a patient and diffuse large cell lymphoma. Rituximab is approved by the Food and Drug Administration (FDA) for other conditions, but not for diffuse large cell lymphoma.
Patients are being asked to take part in this research study because they have a type of B-cell non-Hodgkin's lymphoma called diffuse large cell and have not received treatment for this. The standard treatment for this type tumor is chemotherapy with CHOP alone, or chemotherapy with CHOP and standard radiation therapy. These standard treatments may cure the lymphoma, but in some patients their lymphoma may come back and will need more treatment.
This research is being done because standard chemotherapy with a combination of drugs called CHOP does not cure all patients with this disease. Monoclonal antibodies are proteins made in the laboratory that can bind to antenna-like receptors on the surface of certain cells. Research using monoclonal antibodies for treatment of lymphoma has shown that antibodies such as rituximab that bind to the CD20 surface antigen on B-cells and B-cell lymphoma cells are active treatments. Rituximab has been combined with CHOP (R-CHOP) as treatment for diffuse large cell lymphoma in more advanced stages. This study will use R-CHOP for stages 1 and 2 diffuse large cell lymphoma. Large cell lymphomas can also respond to radiation therapy (RT). RT is usually delivered with a machine that delivers the radiation to the area of the tumor. Radioactive molecules can now be attached to rituximab to deliver the radiation therapy with the help of the antibody. This allows the radiation therapy to be targeted directly to the tumor with the hope that nearby normal cells are not adversely effected. Attaching a radioactive molecule to the antibody appears to increase the effectiveness of these antibody treatments. In this study, all patients will get the same treatment. There is no placebo treatment. In summary, patients can consider this treatment as containing the standard chemotherapy (CHOP) with the addition of the rituximab and the Zevalin and potentially traditional radiation therapy.
Read more
N0682, A Phase II Study of Denileukin Diftitox in Combination with Rituximab (Rituxan) in Previously Untreated Follicular B-cell Non-Hodgkin's Lymphoma Patients
Patients are being asked to take part in this research study because they have follicular B-cell non-Hodgkin's lymphoma and have not had any chemotherapy or radiation treatment.
This research study is being done to find out what effects, good and/or bad, the drug denileukin diftitox combined with rituximab has on the patient and their follicular B-cell non-Hodgkin's lymphoma.
It is important to realize that while rituximab is frequently used as initial treatment for
this type of lymphoma, chemotherapy is also often used in combination with rituximab as
the first treatment for follicular lymphoma. Treatment with chemotherapy plus rituximab may result in more patients responding to treatment and for a longer time, but also in more side effects.
While doctors hope rituximab and denileukin diftitox will be more useful against cancer compared to rituximab alone or rituximab in combination with chemotherapy drugs, there is no proof of this yet.
Read more
Response-Adapted Therapy for Aggressive non-Hodgkins Lymphomas (NHL) based on early [18F] FDG-PET Scanning
This study is being done to find out if making the treatment stronger in patients whose tests show that they are at high risk for their cancer coming back will improve their chances staying cancer-free.
Read more
SG040-0005, A Randomized, Phase IIb Placebo-controlled Study of RICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for Second-line Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Patients are being asked to take part in this research study to test whether a new drug called SGN-40, added to a commonly used drug combination of antibody (rituximab) and chemotherapy drugs (ifosfamide, carboplatin, and etoposide) called R-ICE, is safe and will improve the outcome for participants with diffuse large B-cell lymphoma (DLBCL) that has relapsed or failed to go away completely after initial treatment.
SGN-40 is a type of drug called a monoclonal antibody (the same type of drug as Rituxan or Mab Thera, which patients have previously received). Monoclonal antibodies are proteins that are designed to attack specific targets on cells. SGN-40 is an antibody which is made from human protein and reacts with a target, CD40, on white blood cells and tumor cells. CD40 is found on almost all DLBCL tumors.
Read more
Study of IDEC-Y2B8 in the Treatment of Non-Hodgkin's Lymphoma
This study is being done to learn about the effectiveness and side effects of two doses of IDEC-Y2B. It will use radioimaging techniques to try to predict the effectiveness and safety of the investigational drug.
Read more
Study of the Monoclonal Antibody, Bevacizumab (Avastin) and CHOP (A-CHOP) (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Combination for Patients with Lymphoma Types of Peripheral T-Cell or Natural Killer Cell Neoplasms
This study is being done to find out what effects, good and/or bad, bevacizumab, given with a standard chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine and prednisone, has on a patient and their type of lymphoma.
The combination of these treatments is called standard chemotherapy (A-CHOP).
Adding bevacizumab to the A-CHOP may improve the delivery of the chemotherapy to the patient's tumor. Bevacizumab is investigational, meaning that it has not been approved by the U.S. Food and Drug Administration (FDA) for use in this type of cancer.
Read more
.
